H. Mayer

FTY720 and everolimus in de novo renal transplant patients at risk for delayed graft function: results of an exploratory one‐yr multicenter study

H. Sollinger, H. Tedesco-Silva, R. Shapiro, 2009, Clinical transplantation.

Everolimus in pediatric de nova renal transplant patients1

J. Kovarik, P. Niaudet, J. Mahan, 2003, Transplantation.

Therapeutic Drug Monitoring for Everolimus in Heart Transplant Recipients Based on Exposure–Effect Modeling

J. Kovarik, R. Starling, H. Schmidli, 2004, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia

J. Chang, R. Marcus, R. Powles, 2001, Leukemia.

Therapeutic drug monitoring for everolimus in kidney transplantation using 12‐month exposure, efficacy, and safety data

Heinz Schmidli, J. Kovarik, C. Ponticelli, 2005, Clinical transplantation.

FTY720 Versus Mycophenolate Mofetil in De Novo Renal Transplantation: Six-Month Results of a Double-Blind Study

F. Schena, C. Sommerer, P. Lang, 2007, Transplantation.

Everolimus dose recommendations in de novo heart transplantation - TDM simulations

D. Renlund, D. Mancini, R. Starling, 2003 .